breast cancer breast cancer , Taxane-based chemotherapy , biomarkers , peripheral neuropathy
Conditions
Interventions
Breast cancer patients whom received Taxane-based regimen chemotherapy
Prevention
Breast cancer patients
Sponsors
anesthesiology department , faculty of medicine , Chiangmai university
Cardiac Electrophysiology Research and Training Center (CERT)
Eligibility
Sex/Gender
All
Age
20 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age > 20 years old 2. Breast cancer patients whom received Taxane-based regimen chemotherapy 3. Patients whom received the informed consent to participate this study 4. Ability to communicate and understand the Thai language 5. Ability to cooperate in completing the questionnaire surveys.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of breast cancer recurrence and prior chemotherapy treatment for the initial diagnosis 2.Patients receiving concurrent neurotoxic medications including antiretroviral drug (stavudine, zidovudine), immunosuppressant (tacrolimus, cyclosporine), antimicrobial agent (prolong use metronidazole and linezolid, isoniazid), phenytoin, amiodarone, thalidomide and lenalidomide 3.Patients who have preexisting peripheral neuropathy such as diabetic neuropathy, Uremic neuropathy, vitamin B1,B12 deficiency, Guillain-Barre Syndrome, Idiopathic Peripheral Neuropathy, Post-Herpetic Neuralgia, HIV-Associated Neuropathy 5.Patient refusal 6.Patients with confirmed metastatic disease at the time of recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Risk factors of CIPN 1 month after finish Taxane-base chemotherapy the European Organization for Research and Treatment of Cancer CIPN20 (EORTC-CIPN20) and the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of systemic oxidative stress, inflammatory cytokines, and metabolomic profiles with CIPN development ,Incidence of chemotherapy induced peripheral neuropathy ,Impact of CIPN 1 month after finish Taxane-base chemotherapy oxidative stress level , European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) , Hospital anxiety and depression scale (HADS) Thai version | — |
Countries
Thailand
Contacts
Public ContactPassakorn Sawaddirak
Chiang Mai University
Outcome results
None listed